Related Experiment Videos
[Vaccinal cell therapy in melanoma].
Véronique Quillien1, Thierry Lesimple, Louis Toujas
1Centre régional de lutte contre le cancer de Rennes, rue de la Bataille Flandres-Dunkerque, CS 44229, 35042 Rennes, France. v.quillien@rennes.fnclcc.fr
Bulletin Du Cancer
|November 12, 2003
Summary
Cell vaccination therapy for melanoma has evolved over 15 years, now using advanced methods like dendritic cells. Current treatments show objective tumor responses in about 10% of patients, with ongoing research for improved efficacy.
Area of Science:
- Oncology
- Immunotherapy
- Cellular Therapy
Context:
- Melanoma treatment landscape
- 15-year experience with cell vaccination
- Evolution from inactivated tumor cells to novel approaches
Purpose:
- Summarize advancements in melanoma cell vaccination therapy
- Highlight current treatment options and response rates
- Outline the research and clinical trial pathway for novel therapies
Summary:
- Initial melanoma cell vaccination used inactivated tumor cells.
- Current strategies involve synthetic peptide tumor antigens, dendritic cells, and gene transfer.
- Dendritic cell or macrophage-based protocols yield objective tumor responses in ~10% of patients.
Impact:
- Establishes a baseline for cell vaccination efficacy in melanoma.
- Identifies key areas for therapeutic improvement.
- Defines the pre-clinical and clinical trial progression for novel cell-based therapies.